Objectives

Main Goal

SWAN-iCare aims at developing an integrated autonomous device for the monitoring and the personalized management of chronic wounds, mainly diabetic foot ulcers and venous leg ulcers.

Objectives

Most foot and leg ulcers are caused by diabetes and vascular problems respectively but a remarkable number of them are also due to the co-morbidity influence of many other diseases (e.g. kidney disease, congestive heart failure, high blood pressure, inflammatory Bowel disease). More than 10 million people in Europe suffer from chronic wounds, a number which is expected to grow due to the aging of the population.

The core of the project is the fabrication of a conceptually new wearable negative pressure device equipped with Information and Communication Technologies. Such device will allow users to:

  • accurately monitor many wound parameters via non-invasive integrated micro-sensors
  • early identify infections
  • provide remotely an innovative personalised two-line therapy via non-invasive micro-actuators to supplement the negative pressure wound therapy

SWAN-iCare is a novel approach and focuses on the provision of a pioneering two-line therapy at home: a first line based on a negative pressure device and a second line based on the integrated micro-actuators. 

The physician's analysis of the collected data will be the basis for the decision and the remote control of the therapy. The closed-loop approach offered by SWAN-iCare project provides unprecedented levels of care, improves patient's health condition and significantly lowers costs and need for hospitalisation, with obvious advantages for both patients and health care services.

The project follows an iterative validation approach which includes a series of test sessions in-vitro on human biological samples and in-vivo on humans.

The following diagram shows the main technologies involved in SWAN-iCare.

About the Project

Latest News
SWAN-iCare technical integration meeting hosted by ICCS and EXUS

2016-05-09

The SWAN-iCare system has been validated for its end to end connectivity in the five days meeting in Athens 8-12 May 2016


< July, 2017 >
SuMoTueWeThuFrSa
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Consortium

Euroresearch

http://www.euroresearch.biz/


Swissinnov

http://www.swissinnov.com/


CHU Grenoble

http://www.chu-grenoble.fr/


European Wound Management Association Secretariat

http://www.ewma.org/english.html


EXUS (Coordinator), Greece

http://www.exus.co.uk/


Università di Pisa

http://www.unipi.it/index.php/english


Institute of Communications and Computer Systems

http://www.iccs.gr/


Commissariat à l’Energie Atomique et aux Energies Alternatives

http://www-leti.cea.fr/


Smith & Nephew

http://www.smith-nephew.com/


Centre Suisse d’Electronique et de Microtechnique SA

http://www.csem.ch/site/


Heamopharm Biofluids

http://www.hbiofluids.com/